Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

64.92USD
26 May 2017
Change (% chg)

$-0.12 (-0.18%)
Prev Close
$65.04
Open
$65.00
Day's High
$65.21
Day's Low
$64.82
Volume
3,685,720
Avg. Vol
9,408,094
52-wk High
$66.80
52-wk Low
$55.10

Latest Key Developments (Source: Significant Developments)

Cerveau Technologies says finalization of a clinical supply agreement with Merck
Thursday, 4 May 2017 11:14am EDT 

May 4 (Reuters) - Cerveau Technologies Inc:Cerveau Technologies Inc. Signs clinical supply agreement with merck for investigational tau imaging agent.Cerveau Technologies says finalization of a clinical supply agreement with merck.Cerveau Technologies- will be responsible for providing access to MK-6240 at multiple sites globally to be used in Merck-specific research initiatives.Cerveau Technologies- will be accelerating technology transfer and site qualification in over 15 sites to provide access to support broad availability.  Full Article

Merck expecting somewhat slower animal health growth
Tuesday, 2 May 2017 09:02am EDT 

May 2 (Reuters) - Merck & Co Inc :Merck & Co says expects growth in animal health to be "more measured" in subsequent quarters.  Full Article

PDL BioPharma announces settlement of Keytruda lawsuit with Merck
Monday, 24 Apr 2017 07:00am EDT 

April 24 (Reuters) - PDL BioPharma Inc ::PDL BioPharma announces settlement of Keytruda patent infringement lawsuit with Merck.PDL BioPharma Inc - under terms of agreement, Merck will pay company a one time, lump-sum payment of $19.5 million.PDL BioPharma Inc - company will grant Merck a fully paid-up, royalty free, non-exclusive license to certain of company's Queen et al.PDL BioPharma Inc - in addition, parties agreed to dismiss all claims in relevant legal proceedings.PDL BioPharma Inc - as a result of settlement, expect to recognize $19.5 million in license revenue for q2 ending june 30, 2017.  Full Article

FDA approves Renflexis, biosimilar to Remicade
Friday, 21 Apr 2017 03:54pm EDT 

April 21 (Reuters) - FDA::FDA approves Renflexis, biosimilar to Remicade.  Full Article

Merck reports results from real-world observational study in U.S. Veterans Affairs System evaluating use of ZEPATIER
Friday, 21 Apr 2017 10:00am EDT 

April 21 (Reuters) - Merck & Co Inc : :Real-World observational study in the U.S. Veterans Affairs System evaluating use of Merck’S ZEPATIER® (Elbasvir and Grazoprevir) shows high sustained virologic response rates in patients with chronic Hepatitis C.For evaluable population, 95.6 percent of veterans treated with ZEPATIER achieved primary outcome of sustained virologic response.  Full Article

Atara bio announces collaboration with Merck
Friday, 21 Apr 2017 08:00am EDT 

April 21 (Reuters) - Atara Biotherapeutics Inc ::Atara Bio announces collaboration with Merck to evaluate keytruda (pembrolizumab) in combination with ATA129 in nasopharyngeal carcinoma (NPC).Atara Biotherapeutics-phase 1/2 trial to evaluate safety, pharmacokinetics, pharmacodynamics, preliminary efficacy of combination; planned for initiation in 2018.Collaboration agreement is between Atara Biotherapeutics, Inc. And Merck Sharp & Dohme B.V.Under agreement, trial will be sponsored by Atara Bio.Additional details of collaboration were not disclosed.  Full Article

KYORIN Holdings unit gets license from Merck for drug KRP-114V
Tuesday, 11 Apr 2017 01:45am EDT 

KYORIN Holdings Inc <4569.T> :Says its pharma unit receives license from US firm Merck & Co Inc for drug KRP-114V, a treatment for overactive bladder, owning exclusive rights to develop and commercialize in Asian area.  Full Article

Merck receives complete response letter from the FDA for Tecos study with sitagliptin
Friday, 7 Apr 2017 07:30am EDT 

Merck & Co Inc : Merck receives complete response letter from the U.S. FDA for Tecos study with Sitagliptin . Merck & Co Inc- Merck is reviewing letter and will discuss next steps with FDA .Merck & Co- with the applications, co seeking to include data from Tecos in prescribing information of Sitagliptin-containing medicines.  Full Article

European Medicines Agency's CHMP recommends approval of Merck's keytruda
Friday, 24 Mar 2017 08:13am EDT 

Merck & Co Inc : European Medicines Agency's CHMP recommends approval of Merck's keytruda (pembrolizumab) for the treatment of patients with relapsed or refractory classical hodgkin lymphoma .Merck & Co Inc- decision on approval is expected in Q2 of 2017.  Full Article

U.S. appeals court revives claims against Merck over Fosamax
Wednesday, 22 Mar 2017 08:33am EDT 

U.S. Appeals Court Revives Hundreds Of Claims Alleging Merck & Co : Failed to adequately warn about the risks of fosamax -- court ruling . Decision issued by 3rd u.s. Circuit court of appeals in Philadelphia . Appeals court says lower court judge erred in dismissing claims on the ground they were preempted by federal law . Appeals court says plaintiffs can pursue claim that merck should have warned about risk of thigh bone fractures associated with fosamax . Further company coverage: [MRK.N].  Full Article

More From Around the Web

BRIEF-Optum and Merck collaborate to advance value-based contracting of pharmaceuticals

* Optum and merck collaborate to advance value-based contracting of pharmaceuticals